Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Declines By 28.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 71,326 shares, a decrease of 28.7% from the November 30th total of 100,053 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily volume of 66,726 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily volume of 66,726 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.1% of the shares of the company are short sold.

Hedge Funds Weigh In On Calidi Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CLDI. Armistice Capital LLC purchased a new stake in Calidi Biotherapeutics during the first quarter valued at $1,881,000. Belpointe Asset Management LLC purchased a new stake in Calidi Biotherapeutics during the first quarter valued at approximately $141,000. Finally, Warberg Asset Management LLC bought a new stake in shares of Calidi Biotherapeutics during the 3rd quarter valued at $28,000. 12.53% of the stock is owned by institutional investors.

Calidi Biotherapeutics Price Performance

NYSEAMERICAN CLDI traded up $0.02 during trading hours on Wednesday, hitting $1.17. The company’s stock had a trading volume of 130,169 shares, compared to its average volume of 479,876. Calidi Biotherapeutics has a 12 month low of $1.10 and a 12 month high of $19.20. The company’s 50 day simple moving average is $1.43 and its two-hundred day simple moving average is $2.86. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its earnings results on Thursday, November 13th. The company reported ($2.21) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.